LymphoSign is a pharmaceutical company that focuses on the development of drugs for blood cancers. Founded in 2000, the company has been pioneering pharmaceuticals in the fight against blood cancers. Acquired by Aegera Therapeutics in August 2007, LymphoSign is based in Markham, Canada. Its last investment of $5.90M was a Series A investment led by GeneChem and VenGrowth Asset Management on 03 July 2003. LymphoSign operates in the Biotechnology, Health Care, and Medical Devices industries.
LymphoSign
Pioneering pharmaceuticals in the fight against blood cancers since 2000
Founded 2000
1 employees
Series A
Total: $5.90M
Biotechnology, Health Care +1
General Information
Company Name
LymphoSign
Founded Year
2000
Employees
1
Industries
Biotechnology, Health Care, Medical Devices
Funding Stage
Series A
BounceWatch is an independent company data service, not affiliated with LymphoSign. To contact LymphoSign, visit lymphosign.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does LymphoSign compare?
A PDF of LymphoSign and up to 10 competitors you pick: team, funding, traffic and every dated move of the last six months. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting LymphoSign soon?
A one-page PDF brief: what it does, key facts, the last year of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About LymphoSign
Taxonomy: pharmaceuticals, blood cancers, drug development, acquisition, oncology, clinical trials, therapy development, biopharmaceuticals
Funding Rounds & Investors (1)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series A | $5.90M | 2 |
GeneChem, VenGrowth Asset Management
|
03 Jul 2003 |
LymphoSign Alternatives & Competitors
View All Alternatives
LymphoSign vs
Pioneering advanced treatments for blood cancers, delivering innovative Phase II clinical trials wit...
Series C
Biotechnology, Health Care
LymphoSign vs
ABM Therapeutics
United States
An innovative drug discovery company focusing on targeted therapy for brain cancers as well as brain...
Series B
5 employees
Biopharma, Biotechnology
LymphoSign vs
Prescient Therapeutics
Australia
A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...
Post-IPO Equity
14 employees
Biopharma, Biotechnology
FAQ About LymphoSign
Pioneering pharmaceuticals in the fight against blood cancers since 2000
LymphoSign was founded in 2000.
LymphoSign operates in Biotechnology, Health Care and Medical Devices. Its work centres on pharmaceuticals, blood cancers, drug development and acquisition.
LymphoSign has approximately 1 employees.
LymphoSign has completed 1 funding round, raising a total of $5.90M. The latest funding stage is Series A.
Top alternatives and competitors to LymphoSign include Salmedix, ABM Therapeutics, Prescient Therapeutics, Pharmasset, Inc., Rexahn Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
LymphoSign and Salmedix are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for LymphoSign, https://bouncewatch.com/company/lymphosign, updated 27 December 2024. When citing, please name BounceWatch and link this page.
